NewsBenzingaReported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks Reported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks Benzinga 2026.10.12 08:05 (GMT+0) Open on Benzinga Other news Why Is IREN Stock Surging Monday? 'US Banning Chinese AI DeepSeek From Government Agency It Systems' - Reuters News TD Cowen Maintains Buy on Element Fleet Mgmt, Lowers Price Target to C$31 Cleveland-Cliffs Q3 2026 Earnings Call Transcript On Sunday October 18, 2026 TeraWulf CEO Paul Prager Posted On X "$WULF is NOT a neocloud. $WULF IS an energy infrastructure company. We match long term investment grade energy supply with long term HPC/AI off-take. We finance our projects competitively... Cosmos Health Expects Q4 Sales Of ~$15M, Gross Profit Of ~$10.5M With Gross Margin Of ~70%
On Sunday October 18, 2026 TeraWulf CEO Paul Prager Posted On X "$WULF is NOT a neocloud. $WULF IS an energy infrastructure company. We match long term investment grade energy supply with long term HPC/AI off-take. We finance our projects competitively...
